Q2 2024 Earnings Estimate for Fate Therapeutics, Inc. (NASDAQ:FATE) Issued By HC Wainwright

Fate Therapeutics, Inc. (NASDAQ:FATEFree Report) – Investment analysts at HC Wainwright raised their Q2 2024 EPS estimates for Fate Therapeutics in a report released on Thursday, May 16th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will earn ($0.40) per share for the quarter, up from their prior estimate of ($0.47). HC Wainwright currently has a “Neutral” rating and a $5.00 price target on the stock. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.90) per share. HC Wainwright also issued estimates for Fate Therapeutics’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at $1.93 EPS.

Fate Therapeutics (NASDAQ:FATEGet Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.47). Fate Therapeutics had a negative net margin of 2,933.79% and a negative return on equity of 46.49%. The firm had revenue of $1.93 million during the quarter, compared to analyst estimates of $0.80 million. During the same period last year, the firm posted ($0.19) earnings per share.

Other research analysts have also issued reports about the stock. Morgan Stanley lifted their price objective on shares of Fate Therapeutics from $3.00 to $7.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 27th. BMO Capital Markets cut their price target on shares of Fate Therapeutics from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, May 10th. Oppenheimer reissued a “market perform” rating on shares of Fate Therapeutics in a research note on Tuesday, February 27th. Wedbush reaffirmed a “neutral” rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Monday, May 6th. Finally, Canaccord Genuity Group decreased their price target on Fate Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Fate Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $6.58.

Get Our Latest Research Report on Fate Therapeutics

Fate Therapeutics Price Performance

NASDAQ:FATE opened at $3.70 on Monday. The firm has a market capitalization of $421.17 million, a price-to-earnings ratio of -1.93 and a beta of 1.80. The business has a 50 day simple moving average of $5.51 and a 200-day simple moving average of $4.86. Fate Therapeutics has a 1 year low of $1.63 and a 1 year high of $8.83.

Hedge Funds Weigh In On Fate Therapeutics

Institutional investors have recently bought and sold shares of the business. Fox Run Management L.L.C. purchased a new stake in Fate Therapeutics during the third quarter worth $25,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Fate Therapeutics during the 3rd quarter worth $30,000. Epiq Partners LLC bought a new stake in Fate Therapeutics during the fourth quarter valued at about $38,000. RPO LLC purchased a new position in Fate Therapeutics in the fourth quarter valued at about $46,000. Finally, Victory Capital Management Inc. raised its holdings in Fate Therapeutics by 22.8% in the fourth quarter. Victory Capital Management Inc. now owns 12,504 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 2,322 shares in the last quarter. 97.54% of the stock is owned by hedge funds and other institutional investors.

Fate Therapeutics Company Profile

(Get Free Report)

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.

Featured Stories

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.